Trial Profile
A Randomized, Double-blind, Controlled Trial Comparing Nitazoxanide Plus Lactulose With Lactulose Alone Treatment of Overt Hepatic Encephalopathy
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 05 Aug 2019
Price :
$35
*
At a glance
- Drugs Nitazoxanide (Primary) ; Lactulose
- Indications Hepatic encephalopathy
- Focus Therapeutic Use
- 17 Oct 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 17 Oct 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 09 Mar 2016 Planned End Date changed from 1 Feb 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.